semaj83/ctmatch_classification huggingface dataset:
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Melanoma Histologically documented cutaneous malignant melanoma which is recurrent or metastatic and is not curable by surgical or other means Patients must have tumour tissue from their primary and/or metastatic tumour available to assess putative molecular markers of response (paraffin block or 12 unstained slides) Presence of clinically and/or radiologically documented disease. At least one site of disease must be unidimensionally measurable as follows Chest X-ray > 20 mm, CT scan (with slice thickness of < 5 mm) >10 mm (longest diameter), Physical exam (using calipers) > 10 mm, Lymph nodes by CT scan > 15 mm measured in short axis All radiology studies must be performed within 21 days prior to randomization (Exception: Within 28 days if negative) Patients must have either maximum tumour lesion size of ≤ 50 mm OR if tumour lesion is > 50 mm, LDH must be ≤ 2.5 x ULN Patients must have a life expectancy of at least 12 weeks Age > 18 years ECOG performance status of 0-1 Previous Therapy  Patients with known HIV, Hepatitis B or Hepatitis C infection History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for > 5 years Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, myocardial infarction, other interventional cardiac procedure within the past 12 months, autoimmune conditions requiring chronic immunosuppressive therapy, or psychiatric illness/social situations that would limit compliance with study requirements Patients may not have received any other investigational agents within 28 days of study entry, and may not receive concurrent treatment with other anti-cancer therapy or investigational agents while on protocol therapy Patients with known brain metastases or history of CNS metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. A head CT or MRI is required on all patients to rule out brain metastases Pregnant or lactating women. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with rIL-21 or dacarbazine, breastfeeding should be discontinued if the mother is treated with protocol therapy Prohibited Medications: Long Term (> 7 days) Systemic Corticosteroids (e.g. prednisone, dexamethasone, etc.) because these may counteract the stimulatory effects of rIL-21 on lymphocytes. (Note: Topical steroids are allowed)
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lung Cancer All patients with CT identified pulmonary nodules not deemed to be visualizable during VATS who are candidates for VATS resection  Inability to consent for the study Patients less than 18 years old Patients with pulmonary nodules easily located during VATS Patients with tumours extending to visceral pleura or chest wall Patients who have chest anatomy precluding VATS resection
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Yield of Cryo Biopsy in Lung Cancer Solitary Pulmonary Nodule solitary pulmonary nodule < 4 cm no endobronchial lesion indication for bronchoscopy  coagulopathy pulmonary hypertension pregnancy
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 0.0-18.0,  Craniopharyngioma Obesity Diagnosed with craniopharyngioma for the first time Age at diagnosis 18 years or less of age Agreement from patient's parents or legal guardian as well as the patient for in randomization study Histological diagnosis of craniopharyngioma Age at diagnosis 18 years or less of age Age at primary surgery over 5 years of age Incomplete primary resection Reference radiological confirmation of an incomplete resection Agreement from patient's parents or legal guardian as well as the patient  Age at diagnosis over 18 years of age No QoL measurement for randomization (3 months after surgery)
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Incisional Hernia age ≥18 years asymptomatic/ oligosymptomatic incisional hernia  no hernia detectable by physical examination acute incarcerated hernia emergency hernia repair pain or discomfort associated with the hernia during normal activities local or systemic infection ASA score >3 inability to complete or comprehend the preoperative questionnaire repair with biologic prothesis
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 4.0-22.0,  Medulloblastoma Age at diagnosis at least 4 years or 5 years (according to the policy of the National Brain Tumour Group) and less than 22 years Histologically proven medulloblastoma, including the following variants(WHO classification : classic medulloblastoma, nodular / desmoplastic medulloblastoma, melanotic medulloblastoma, medullomyoblastoma No CNS metastasis on MRI supratentorial, arachnoid of the posterior fossa or spine No clinical evidence of extra-CNS metastasis No tumour cells on the cytospin of lumbar CSF. Central Review of CSF cytology is recommended but not mandatory. It will be left to national policy Radiotherapy to start no more than 40 days after surgery Ability to receive twice daily radiotherapy Vital functions within normal range for their age group CTC grades < 2 for liver, renal, haematological and audiological function  One of the is lacking Brainstem or supratentorial primitive neuroectodermal tumour Atypical teratoid rhabdoid tumour Medulloepithelioma Ependymoblastoma Large cell médulloblastoma Metastatic medulloblastoma (on CNS MRI and/or positive cytospin of postoperative lumbar CSF) Patient previously treated for a brain tumour or any type of malignant disease Patients who are pregnant Females who are sexually active and not taking reliable contraception
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Bronchiectasis Bronchiolitis All patients with bronchiectasis or bronchiolitis  All patients with severe lung disease other than bronchiectasis Active lung infection Active infection other site except the lung
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lung Cancer Participant is a lung cancer patient  Participant is under 18 years old Participant is not a lung cancer patient
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Solitary Pulmonary Nodules Multiple Pulmonary Nodules Renal Neoplasms Adrenal Gland Neoplasms Aortic Aneurysm, Abdominal Liver Neoplasms Adnexal and Skin Appendage Neoplasms Lymphadenopathy Pancreatic Neoplasms No participant sub-populations will be excluded prior to selection (the E1 population will be matched to the Case Group populations) Data from the 15 participating sites from the ACRIN 6664 trial provide a study data set of 2531 participants, broken down into a total target study data set of 520 participants. Participants will be distributed into one of three cohorts as follows The Case Group will target consenting 141 participants from the cases with indeterminate but potentially significant findings (E3/E4s) other than pulmonary nodules The Pulmonary Nodules Case Group will comprise 119 cases with E3/E4 ECFs characterized as pulmonary nodules The E1 Control Group will be drawn from the 866 E1 ECF cases to create a cohort of 260 E1ECF cases. The Control Group for comparison with the Case Group and the Pulmonary Nodules Case Group will be selected at the Biostatistics and Data Management Center (BDMC). The BDMC will match E1 141 controls to the 141 case-group participants with indeterminate but potentially significant findings (E3/E4s). The BDMC will also match 119 E1 controls to the 119 E3/E4 pulmonary nodules cases. Controls will be matched by site, age caliper (5 years), and sex where possible. Where an appropriate match cannot be obtained, the matching will be relaxed. If potential participants decline study consent, we will then best-match additional cases for the appropriate group to maintain target populations. Any additional cases beyond the initial 520 participants identified for medical record collection will be matched as feasible
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Small Bowel Obstruction Gastrointestinal Hemorrhage Patients 18 years and older Patient or proxy willing to provide informed consent Patients who require placement of a nasogastric/orogastric tube, in the ED or ICU, as standard of care, AND a member of the study staff is available and present for NG/OG tube placement It is anticipated that the patient will remain in the ED/ICU in order to obtain RightSpot pH Indicator reading and verifying CXR  Patients less than 18 years of age Patient or proxy unwilling or unable to provide informed consent Patient with known or suspected pregnancy
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Solitary Pulmonary Nodule Multiple Pulmonary Nodules Subjects who meet all of the following may be enrolled in this Study Subject is male or female, age 18 or older Subject has undergone CT scan of the lung(s) that indicates one or more nodules or lesions suspicious for lung cancer Subject's pulmonary nodule or lesion is greater than 4mm. Size is determined by the largest nodule or lesion dimension identified from CT imaging Subject meets one or more of the following conditions indicated for a tissue biopsy of the lung indicated for surgical resection of the lung being followed by CT for nodule growth within a 1-year time frame* subject must receive at least one follow-up CT by their 1-year enrollment anniversary or within 60 days after their 1-year enrollment anniversary to continue in the Study Subject must be able to receive a ProLung Test  The following will disqualify a subject from enrollment into this Study Subject has an implanted electronic device in the chest Subject receiving therapy for suspected chest infection such as fungal infection or tuberculosis Subject with diagnosed malignancy other than lung cancer who has 2 or more suspicious pulmonary nodules Subject has received an invasive medical or surgical procedure within the thoracic cavity within 30 days prior to the ProLung Test or within the previous 14 days for a bronchoscopic procedure Subject presents with an anomalous physical or anatomical condition that precludes ProLung Test measurement Subject will have undergone unusually strenuous exercise within 24 hours Subject who has significant systemic diseases such as uncontrolled diabetes, advanced heart failure, or a recent myocardial infarction, or other medical condition such as severe morbid obesity that in the judgment of the Principal Investigator would make him/her unsuitable for the Study
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Hypotension Arterial pressure <100 mm/Hg at presentation At least one of the following symptoms Unresponsive Syncope Impaired mental status Respiratory distress Severe malaise and fatigue  Patients undergoing cardiopulmonary resuscitation Trauma patients Electrocardiographic and clinical diagnosis of STEMI or Clear cause of shock that needs immediate intervention (hemorrhage, gastrointestinal bleeding, drugs overdose) Late evolution of shock state in a patient already treated with known diagnostic tests
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 16.0-90.0,  Pneumothorax Radiologic diagnosis of pneumothorax Clinical need to perform a CT scan Ability to perform the lung ultrasound imaging within 20 minutes from the CT study  age less than 16 years
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Primary Graft Dysfunction All consecutive bilateral lung transplant recipients  Immediate need for extracorporeal life support following transplant (those requiring ECLS four hours after intensive care admission can be included as the investigators would have obtained some ELWI measurements) Contraindications to femoral artery catheterization (eg, abdominal aortic aneurysm)
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 20.0-40.0,  Assess the Efficacy of Differentiated and Undifferentiated Stem Cell Therapy in Improving Endometrial Receptivity. ICSI candidates with repeated implantation failure and history of development of good embryos in previous ICSI cycles Advanced maternal age above 38 years Poor endometrial response to ovulation induction drugs Endometrial atrophy  Presence of infection in the form of vaginitis, cervicitis or hydrosalpinx Presence of uterine abnormality as uterine septum Presence of any pathology distorting the uterine cavity as submucus polyp or submucus myoma Marked sperm morphology abnormality High FSH > 12 IU
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pneumonia All patients who present to the ED with respiratory symptoms suspicious for pneumonia In whom the treating physician believes would benefit from diagnostic imaging  Patients who arrive at the ED with a previously performed CXR Unstable patients with life-threatening injuries who require ongoing resuscitation
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 40.0-75.0,  Lung Cancer ages 40-75 years If ages 40-59, then one of the following needs to be met Current or ex-smoker with >25 pack years and a family history of lung cancer(parent or sibling) OR current or ex-smoker with > 25 pack years and COPD OR current or ex-smoker with a > 35 pack year history If ages 60-75, then one of the following additional needs to be met Current or ex-smoker with >25 pack years and a family history of lung cancer (parent or sibling) OR Current or ex-smoker with >25 pack years and COPD OR Current or ex-smoker with a >30 pack year history Subject is able to return to Cleveland Clinic for annual follow-up screening  Current health requires oxygen Have had a chest x-ray or CT of the chest within the last 6 months Previous pneumonectomy Lobectomy of the lung within the last 5 years Diagnosed malignancy within the last 5 years, excluding non-melanoma skin cancer, carcinoma in situ of the cervix and localized prostate cancer A medical condition that would prevent treatment for lung cancer Within the last 6 weeks, one of the following has occured A new cough or chronic cough that has gotten worse Either new shortness of breath, or any worsening of shortness of breath A cough producing blood
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Transitional Cell Carcinoma Written informed consent Age ≥ 18 Life expectancy ≥ 12 weeks Patients with histology/cytology confirmed Transitional Cell Carcinoma (TCC) including mixed pathology with predominantly TCC, with locally advanced (T4b) or metastatic (lymph node or visceral) TCC arising from bladder or upper urinary tracts Treated patients with incidental prostate cancer (pT2, Gleason ≤ 6) and PSA (Prostate Specific Antigen) ≤ 0.5 ng/mL are eligible Measurable disease as per 1.1 ECOG Performance Status 0-1 Previously received first line platinum based treatment Recurrence within 12 months (by version 1.1) from last cycle of chemotherapy  Previous therapy with a taxane Pure non TCC histologies Grade II or more peripheral neuropathy Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrolment in the study Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus) Inadequate organ and bone marrow function as evidenced by Hemoglobin < 9.0 g/dL Absolute neutrophil count < 1.5 x 109/L Platelet count < 100 x 109/L AST/SGOT and/or ALT/SGPT > 2.5 x ULN
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-48.0,  Cerebral Oxygen Saturation During Spinal Anesthesia for Cesarean Delivery Term healthy parturients  Body Mass Index > 35 preeclampsia neurological,cardiovascular, respiratory disease
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 8.0-17.0,  Persons With Frontal Lobe Damage With no Specific Language Disorder frontal lobe damage at least one year after injury native hebrew speaker  specific language disorder premorbid learning disability
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 55.0-74.0,  Lung Carcinoma   Men and women who at the time of randomization are less than 55 or greater than or equal to 75 years of age Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer Individuals with known prior cancer of the colon, rectum, lung, prostate (men only) or ovary (women only) This includes primary or metastatic PLCO cancers Individuals with previous surgical removal of the entire colon, one lung, or the entire prostate (men only) Until October 1996, women with previous surgical removal of both ovaries were excluded from the trial. In order to increase the enrollment of women into the trial, beginning in October 1996, these women were no longer excluded for this reason Individuals who are participating in another cancer screening or cancer primary prevention trial Males who have taken Proscar/Propecia/finasteride in the past 6 months NOTE: Individuals who are already enrolled in the trial when their physician prescribes finasteride are not prevented from taking this medication. As a result, these participants will continue to be screened and followed just as those participants who are not on finasteride NOTE: Men who are taking Tamoxifen are not excluded from any part of the PLCO Screening Trial